SUPN
SUPERNUS PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$39.84
+5.17%Year over year
Reported trailing growth
- Revenue
- +24.9%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -89.9%
- Operating cash flow
- -89.4%
Forward estimates
Based on analyst estimates
- Revenue
- +20.4%
- EBITDA
- +2242.1%
- EPS
- +268.1%
Three-year CAGR
- Revenue
- +2.5%
- EBITDA
- -34.8%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -26.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026